United Therapeutics Corporation: Advancements in Organ Transplant Alternatives Upping Their Game?

United Therapeutics Corporation reported a robust third-quarter performance for 2024, marking six consecutive quarters of record revenue. The company achieved a revenue total of $749 million, reflecting a 23% increase from the same period in 2023. This financial success is largely attributed to strong double[1]digit growth in key products such as Tyvaso, Orenitram, and Unituxin, as well as an increased patient base for these therapies. Tyvaso, specifically, solidified its position as the leading prescribed prostacyclin treatment in the U.S., with revenues climbing to $434 million, a 33% rise from the previous year.